BACKGROUND The integrated diagnostics (ID) algorithm is an implantable device-based tool that collates data pertaining to heart rhythm, heart rate, intrathoracic fluid status, and activity, producing a risk score that correlates with 30-day risk of heart failure (HF) hospitalization.
Introduction
Heart failure (HF) is an issue of significant and increasing burden to population health and health care resources.
Approximately 5.1 million Americans suffer from HF with more than 1 million hospitalizations on an annual basis and an average readmission rate of 25% at 1 month. 1 This incurs a $40 billion cost to the health care system annually, with over half of this cost due to hospital admissions. A number of prediction tools have been developed in an attempt to identify patients with HF at high risk of death. 2, 3 These tend to require patient evaluation, tests, and laboratory results that must be updated each time a patient's risk is reassessed. The integrated diagnostics (ID) algorithm is an implantable device-based tool that collates data pertaining to heart rhythm, heart rate, intrathoracic fluid status, and activity, Dr Gula has received honoraria from Medtronic. Dr Yee has received consulting fees from Medtronic. Ms Koehler is an employee of Medtronic. Dr Sarkar is an employee of Medtronic. Dr Sharma is an employee of Medtronic. Dr Redfearn has received consulting fees from St Jude Medical. Dr Manlucu has received honoraria from Medtronic. Dr Tang has received consulting fees from Medtronic and St Jude Medical; he has also received research funding from Medtronic. Address reprint requests and correspondence: Dr Lorne J. Gula, Western University, 339 Windermere Rd, London, Ontario, Canada N6A 5A5. E-mail address: lgula@uwo.ca. producing a risk score that correlates with a 30-day risk of HF hospitalization. 4 It is a dynamic assessment tool in which variables are continuously updated, and it is widely available in existing implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT) devices. The cohorts initially used for derivation [5] [6] [7] and validation [8] [9] [10] of the ID risk score were drawn from prospective nonrandomized studies and included only patients with CRT-D (CRT with defibrillation capability) devices. We sought to further validate the ID algorithm and test its association with HF hospitalization as well as with the incidence of HF symptoms in patients enrolled in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT), 11 a large international clinical trial of patients with congestive HF including both ICD and CRT-D devices.
Methods
RAFT was a multicenter randomized controlled study in patients with New York Heart Association (NYHA) class II or III symptoms, left ventricular systolic dysfunction, and a wide QRS complex. The rationale, design, inclusion/exclusion criteria, and end points have been published previously. 12 Briefly, 1798 patients were enrolled and randomized to ICD or CRT-D. The primary outcome was a composite end point of death from any cause or hospitalization for HF. Hospitalization for HF alone was a prespecified secondary outcome and was defined as admission to hospital for more than 24 hours for treatment of HF. Patients with an implanted device with the capability of monitoring and storing all elements of the ID algorithm were included in this analysis.
Diagnostic measures of the ID algorithm include the following 5 variables with measurement thresholds as determined by previous studies: 8, 13, 14 (1) Intrathoracic impedance, measured from the right ventricular coil to the pulse generator, was used to compute the OptiVol fluid index (FI), reflecting volume status and lung congestion 15 and stratified to 4 levels of worsening lung congestion: level 1: 0 r FI o 30 ohm-days; level 2: 30 r FI o 60 ohm-days; level 3: 60 r FI o 100 ohm-days; level 4: FI Z100 ohm-days. (2) Nighttime heart rate (NHR), the average heart rate between midnight and 4 AM, was stratified to 2 levels: level 1: NHR 55-85 beats/ min; level 2: NHR Z85 beats/min, r55 beats/min, or increasing. (3) Number of minutes of patient activity (ACT) per 24-hour period as detected by the device's piezoelectric sensor was stratified to 2 levels: level 1: ACT 460 min/d; level 2: ACT r60 min/d or decreasing activity. (4) Heart rate variability (HRV) was measured as the SD of 5-minute medians of intervals over a 24-hour period and stratified to 2 levels: level 1: HRV standard deviation of normal intervals (SDNN) 460 ms; level 2: HRV SDNN r60 ms or decreasing HRV. (5) A combined measure of heart rhythm included 4 factors measured over 24 hours: atrial fibrillation burden Z1 h/d, mean ventricular rate during atrial fibrillation Z90 beats/min, a single shock for ventricular tachyarrhythmia whether ventricular tachycardia or ventricular fibrillation or 5 ventricular tachyarrhythmia episodes treated with antitachycardia pacing in 24 hours, and percent pacing in patients with a CRT device r90% (in whom 100% paced beats is intended), and this combined measure was stratified to 2 levels: level 1: only 1 of 4 criteria met; level 2: 2 or more criteria met. These 5 measures were then entered in a Bayesian belief network 16 to generate a summary HF risk score. The risk score was categorized into low, medium, or high risk for HF. A schematic of the ID algorithm is displayed in Figure 1 .
Patients were seen for follow-up 1 month after device implant and every 6 months, consisting of device interrogation, full clinical assessment, and survey of health changes since the last visit. Patients and the treating health team including physicians were blinded to study arm assignment, while a separate health care team including implanting and device management physician was unblinded. All events were adjudicated by an independent, blinded end-point committee. The study was coordinated and database maintained by the Cardiovascular Research Methods Center at the University of Ottawa Heart Institute. The Canadian Institutes of Health Figure 1 Schematic of the ID algorithm. Participants are assigned a value for each variable on a daily basis. These values are then combined with a risk score that is categorized into low, medium, or high risk. HF ¼ heart failure; ID ¼ integrated diagnostics.
Research and Medtronic provided funding for the study through a peer-reviewed process, but did not participate in the conduct of the trial, collection, or assessment of the parent trial data.
For the HF admission analysis, monthly evaluations of ID parameters were simulated to occur every 30 days. For each monthly evaluation, the maximum HF risk score was determined from the daily risk score for the previous 30 days. This maximum HF risk score was used to categorize the monthly evaluations into low (risk score o0.054), medium (risk score 0.054-0.20), and high (risk score Z0.20) risk. HF exacerbation was evaluated in the 30 days after the monthly evaluation. Monthly evaluations were included in the analysis if there were 30 days of diagnostic data available before the evaluation and 30 days of follow-up available after the monthly evaluation to evaluate the risk of HF exacerbation. For the analysis of signs and symptoms of HF, findings on follow-up visits were assessed according to the highest ID risk score in the 30 days preceding clinical assessment. Patients implanted with CRT-D generators without left ventricular leads (n ¼ 155) were included in the ICD-only device group. A generalized estimating equation model was used to estimate the relative risk along with the 95% confidence intervals (CIs) to account for the multiple evaluations in each patient. An interaction term was tested for all pairwise groupings of ID variables with regard to HF admission. All statistical analyses were performed using SAS version 9.2 (SAS Institute, Inc, Cary, NC).
Results
The results of RAFT have been published previously. Of all the study participants enrolled in RAFT, 1224 patients received devices capable of monitoring and storing all 5 ID variables and were included in this analysis. The mean age was 66 Ϯ 9 years, and 83% were men. Of these patients, 741 received CRT-D devices and 483 only ICD. Baseline characteristics are summarized in Table 1 . Comparisons were made between these 1224 patients and the 574 patients who could not be included. Compared with those excluded, patients included in this analysis more often had a CRT-D device (61% vs 25%; P o .001), more NYHA class II HF (as opposed to NYHA class III HF) (87% vs 66%; P o .001), less ischemic etiology of HF (65% vs 70%; P ¼ .044), less renal dysfunction (17% vs 25%; P o .001), less diuretic use (82% vs 89%; P ¼ .001), less nitrate use (27% vs 32%; P ¼ .016), and less antiarrhythmic medication use (14% vs 19%; P ¼ .011). Other baseline variables in Table 1 did not differ significantly.
Of the 1224 ID patients, 37,861 months of follow-up data were available, with 258 hospitalizations for HF (event rate 0.68% per month). The ID algorithm assessed 41% of total months as low risk, 49% as medium risk, and 10% as high risk. There were 33 HF admissions during low-risk months (event rate 0.21% per month), 123 during medium-risk months (0.66% per month), and 102 during high-risk months (2.61%) ( Table 2 ). Compared with low-risk months, the relative risk of HF admission during medium-risk months was 2.9 (2.0-4.4) and during high-risk months it was 10.7 (6.9-16.6). The cumulative risk of hospital admission is illustrated in Figure 2 .
Patients in the ICD and CRT-D groups were assessed separately. Details are presented in Table 3 . The number of low-, medium-, and high-risk months were similar between the 2 groups. The overall incidence of HF hospitalization was 0.73% per month in patients with CRT-D and 0.60% in patients with ICD only. The ID algorithm showed event rates of 0.21% per month in patients with CRT-D and 0.22% per month in patients with ICD, which were determined as low risk; 0.74% in patients with CRT-D and 0.53% in patients with ICD only, which were determined as medium risk; and 2.73% in patients with CRT-D and 2.40% in patients with ICD only, which were determined as high risk. The relative risk of HF hospitalization in the medium-risk group (compared with the low-risk group) was 3.3 (2.0-5.4) in patients with CRT-D and 2.3 (1.2-4.6) in patients with ICD only, and in the high-risk group it was 11.3 (6.5-19.7) in patients with CRT-D and 9.6 (4.6-19.7) in patients with ICD only.
Patients with NYHA class II and III HF were assessed separately. Details are presented in Table 4 . Patients with NYHA class III HF had a higher rate of HF hospitalization than did patients with NYHA class II HF (1.16% per month vs 0.60% per month), and there were progressively increasing HF hospitalization rates in both NYHA class II HF and NYHA class III HF from low to medium to high risk as assigned by the ID algorithm. The relative risk of HF hospitalization in the medium-risk group (compared with the low-risk group) was 2.9 (1.8-4.5) in patients with NYHA class II HF and 3.0 (1.2-7.3) in patients with NYHA class III HF, and in the high-risk group it was 10.7 (6.4-17.8) in patients with NYHA class II HF and 9.0 (3.8-21.6) in patients with NYHA class III HF.
Univariable analysis demonstrated a significant association of each of the 5 factors with HF hospitalization (see Online Supplemental Table 1 ). In multivariable analysis, each factor remained independently associated with HF hospitalization (Table 5 ). Increasing thoracic impedance was associated with a relative risk of hospitalization of 3.9 (2.6-5.9), combined heart rhythm 3.1 (1.6-6.0), activity level 2.2 (1.5-3.1), HRV 1.7 (1.2-2.5), and NHR 1.6 (1.2-2.3). There was no significant interaction in any pair of ID variables with regard to hospital admission.
The presence of individual signs and symptoms of HF at follow-up visits was also assessed for correlation with IDdetermined risk. All signs and symptoms with the exception of the presence of S3 or S4 had a significantly higher incidence in high risk than in low risk, and elevated jugular venous pressure, orthopnea/paroxysmal nocturnal dyspnea, and peripheral edema had a significantly higher incidence in medium risk than in low risk. Details are presented in Table 6 .
Discussion
In RAFT, a trial of 1798 patients with HF, 23% of the patients were hospitalized with HF over a mean follow-up period of 40 months. This is representative of the enormous, and increasing, health care and economic burden presented by HF exacerbation. Patients at highest risk typically have impaired left ventricular function with HF symptoms. They therefore have an indication for an ICD or CRT-D device, [17] [18] [19] [20] which provides an ongoing means for the collection and analysis of physiological parameters. In contrast to conventional risk scores that are static by design, a risk score based on implantable device data can be continuously updated. It can potentially detect high or increasing risk of HF exacerbation before hospitalization is required and provide a timely signal to physicians through remote monitoring. This may prevent hospitalization by signaling the need for change to ongoing therapy, thereby potentially reducing morbidity and costs.
The ID algorithm has been developed on the basis of the testing of a number of physiological parameters, incorporating those demonstrating strongest association with HF exacerbation. 4 The cohorts initially used to develop the risk score were nonrandomized studies with 921 and 1310 patients for derivation and validation, respectively. The present study establishes the algorithm in the context of a large, multicenter, randomized clinical trial with 37,829 patient-months of follow-up data. Patients enrolled in RAFT had significant left ventricular dysfunction and preexisting HF with at least a moderate risk of exacerbation and hospital admission. The subset of patients included in the present analysis had more biventricular pacing, less renal dysfunction, and less use of diuretics, nitrates, and antiarrhythmic medications than did the average study participant. These differences reflect the fact that OptiVol-capable devices were introduced midway through RAFT at a time when enrollment criteria were altered to include only patients with NYHA class II symptoms and no longer include patients with NYHA class III symptoms. Therefore, patients with NYHA class III symptoms, enrolled early in the trial, are underrepresented. The observed event rate may therefore be an underrepresentation, biasing to some degree against the power of the ID algorithm to estimate HF exacerbation risk.
The rate of HF hospitalization in patients enrolled in RAFT was 0.68% per month, or 1 admission per 146 patient-months of follow-up. This rate reflects a somewhat lower-risk population than did the admission rate of the prior ID validation set 4 (0.93% per month, or 1 admission per 108 patient-months of follow-up). Patients who are determined "low risk" by the algorithm had an HF hospitalization rate of 0.22% per month, those determined "medium risk" had a 2.9-fold higher rate (0.66% per month), and those determined "high risk" had a 10.7-fold higher rate (2.61% per month). Approximately 10% of months were determined high risk and 50% medium risk. On a practical level, adjustment of therapy in response to a high-risk determination would therefore be an infrequent occurrence. Ten thousand high-risk determinations in patients enrolled in RAFT would be associated with 261 HF admissions. If these admissions are preventable with change to therapy, the number of high-risk determinations to prevent 1 hospitalization in patients enrolled in RAFT would be approximately 38. On the basis of the observation that 10% of ID assessments are high risk, 120 of the 1200 participants in the present analysis would be high risk in a given month. In a best-case scenario, if each of the 38 high-risk determinations could potentially save 1 admission by therapy, then approximately 3 HF admissions could be prevented per month. Although this clearly requires a prospective cost-benefit study of ID-directed therapy, it suggests a potential for reduction in morbidity and costs in spite of low incidence of HF admission.
The present study further establishes that each element of the algorithm-thoracic impedance, NHR, physical activity, heart rate variability, and the combined measure of arrhythmia with CRT pacing-shows independent association with HF admission. The strongest association was with high thoracic impedance as measured by OptiVol (relative risk 3.9), followed by the combined heart rhythm counter (relative risk 3.1). The latter incorporates a measure of percent biventricular paced beats and may reflect, to some degree, the effect of CRT on HF symptoms. Prior validation of the ID algorithm has been in CRT-D devices only, and this analysis extends the findings to non-CRT ICD patients. Patients in the ICD arm had a similar rate of HF admission, and Table 3 confirms that the ID algorithm behaved similarly in patients with ICD and patients with CRT-D in terms of number of low-, medium-, and high-risk months assigned and relative risks associated with these designations.
Study limitations
This study has some limitations that should be considered. The ID algorithm is specific to Medtronic devices, and the results are therefore limited to patients with these devices. Clinical signs and symptoms of HF are important aspects of the diagnosis that are not assessed by the device, and although the sensitivity and specificity of the algorithm for specific clinical manifestations are presented in Table 6 , the algorithm is not a substitute for clinical assessment and decision making. We do not have data on how many patients were hospitalized for HF when the ID score was low, how many had a high ID score in the absence of HF, or what costs are associated with these false-negative and false-positive results. All these are essential next steps in evaluating the algorithm and are currently underway.
Conclusion
The risk of HF as determined by a cardiac device-based algorithm correlated with HF admission and with several HF symptoms and signs among patients enrolled in RAFT. This may present a useful adjunct to detect early signs of congestive HF and adjust therapy to reduce morbidity and costs involved with hospital admission. 
